SCHEMBL17434290

SCHEMBL17434290

CCn1c(=O)n(CCOC)c(=O)c2cc(N)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ MAPT P10636 2/20 0.55
▸ GAA P10253 2/20 0.55
▸ GFER P55789 1/20 0.55
▸ PARG Q86W56 5/20 0.52
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ HBB P68871 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ ADORA2B P29275 4/20 0.44
▸ PDE4A P27815 1/20 0.44
▸ ADORA2A P29274 1/20 0.44
▸ PDE4B Q07343 1/20 0.44
▸ PDE4C Q08493 1/20 0.44
▸ PDE4D Q08499 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17434477 0.95 PARG (0.57) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434408 0.92 PARG (0.53) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434221 0.87 PARG (0.59) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL25424313 0.86 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL31135597 0.86 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434394 0.86 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434453 0.86 ALDH1A1 (0.68) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL25724310 0.84 ALDH1A1 (0.43) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL25724066 0.84 PARG (0.44) ALDH1A1PARGADORA2BPDE4AADORA2A
SCHEMBL25724068 0.84 MEN1 (0.54) MAPTKMT2AMEN1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-05 — — US disclosed
US-20160229814-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-11 — — US disclosed
EP-2975031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-01-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229814-A1 HETEROCYCLIC COMPOUND RORB, RORC, RORA ALDH1A1 312/4885KDM4E 728/4885MAPT 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback